ResultsIQ

ResultsIQ › Latest results › Valiant Organics Limited

Valiant Organics Limited Q2 FY26 results deck summary

NSE: VALIANTORG · BSE: 540145

Results deck of 15 Nov 2025, summarised by AI from the filing.

Valiant Organics Q2 FY26 consolidated revenue ₹1,573 mn, EBITDA margin 13.48% and PAT ₹57 mn, recovering from a loss in Q2 FY25.

Key takeaways

  1. H1 result H1-FY26 consolidated revenue ₹3,617 mn (H1-FY25: ₹3,281 mn, 10.2%), EBITDA ₹459 mn with margin 12.69%, PAT ₹139 mn.
  2. Margin change Gross margin improved to 46% in Q2-FY26 from 39% in Q1 FY26 and 36% in Q2 FY25 on better raw-material efficiency and product mix.
  3. Growth driver Revenue growth was supported by better realizations and steady demand conditions, with cost control and lower finance expenses aiding margins.
  4. Risk Consolidated financials of previous periods and YTD results are not comparable after VLL ceased to be a step down subsidiary.

Original filing on BSE

Valiant Organics Limited Q1 FY27 results

As filed: Revenue ₹232 cr (+14% year on year), EBITDA ₹41.6 cr (+73% year on year), PAT ₹29.3 cr (+266% year on year), EBITDA margin 18.0% (+621 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹218 cr (+7% year on year), EBITDA ₹26.5 cr (+32% year on year), PAT ₹15.7 cr (+293% year on year), EBITDA margin 12.2% (+236 bps). Score 69 of 100, Above trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was well above it. EBITDA margin rose 236 bps year on year. Tax rate 11%. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −4.6% in 30 days (Nifty 500: +1.6%).
  • Q3 FY26: Revenue ₹159 cr (−15% year on year), EBITDA ₹15.6 cr (−3% year on year), PAT ₹3.6 cr (−58% year on year), EBITDA margin 9.8% (+123 bps). Score 38 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit before exceptional items growth were in line with it. EBITDA margin rose 123 bps year on year. Consolidated profit -27% but standalone +21%. Profit fell 64% from last quarter. Share price after the results: −22.3% in 28 days (Nifty 500: −8.2%).
  • Q2 FY26: Revenue ₹157 cr (−2% year on year), EBITDA ₹21.0 cr (+300% year on year), PAT ₹6.0 cr, EBITDA margin 13.4% (+1,000 bps). Score 68 of 100, Above trend. Revenue growth was in line with the company's own trend; EBITDA growth was well above it. EBITDA margin rose 1000 bps year on year. Revenue fell 23% from last quarter. Share price after the results: −5.5% in 29 days (Nifty 500: −0.4%).
  • Q1 FY26: Revenue ₹204 cr (+21% year on year), EBITDA ₹24.0 cr (+50% year on year), PAT ₹8.0 cr, EBITDA margin 11.8% (+224 bps). Score 71 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 224 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: +4.0% in 30 days (Nifty 500: +2.2%).
  • Q4 FY25: Revenue ₹204 cr (+15% year on year), EBITDA ₹20.0 cr, PAT ₹4.0 cr, EBITDA margin 9.8% (+1,000 bps). Score 67 of 100, Above trend. Revenue growth was above the company's own trend. EBITDA margin rose 1000 bps year on year. Tax rate 43%. Profit fell 20% from last quarter. Share price after the results: +7.9% in 29 days (Nifty 500: +2.0%).
  • Q3 FY25: Revenue ₹187 cr (+33% year on year), EBITDA ₹16.0 cr (+300% year on year), PAT ₹5.0 cr, EBITDA margin 8.6% (+572 bps). Score 88 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend. EBITDA margin rose 572 bps year on year. Other income 83% of PBT.
  • Q2 FY25: Revenue ₹160 cr (−21% year on year), EBITDA ₹2.0 cr (−87% year on year), PAT −₹12.0 cr (−300% year on year), EBITDA margin 1.3% (−614 bps). Score 0 of 100, Below trend. EBITDA margin fell 614 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 5% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Valiant Organics Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.